involvement we observed that gp130/sIL-6Rb, sIL-6Ra, IL-35, and TSLP serum levels were significant enhanced in MO-BD compared to M-BD subgroup.
TLR-7 expression in these cells. In murine lupus-models, TLR7-deletion has been shown to reduce autoimmune disease. The enhanced TLR-7 signaling pathway in pDC may play an important role in lupus pathology. Background: The SAPHO syndrome has to be considered as a rare subtype of the disease entity of the seronegative spondylarthritis. The characteristic defining symptoms are synovitis, acne, palmoplantar pustulosis (PPP), and hyperostosis with osteitis. In general, most of SAPHO patients complete the diagnostic criteria for spondylarthritis and/or psoriatic arthritis. The etiology of SAPHO syndrome remains unclear so far, autoimmune dysregulations potentially triggered by bacterial infection with propionibacterium acnes has been discussed. Firinu D et. al (Ref.) has previously published data of higher Th17+ lymphocytes in the periphereal blood in SAPHO patients compared with psoriatic arthritis patients or healthy controls. Activation of the TH17 pathway leads to pro-inflammatory effects mediated by interleukin 17 with stimulation of osteoblast, macrophages, and fibroblasts with the consequences of secretion f pro-inflammatory cytokines such as interleukin 6 and 1, TNF alpha, and MMPs. The interleukin 17 blocking agent secukinumab has been introduced in the armentarium of antirheumatic drugs against seronegative spondylarthritis including psoriatic arthritis. Objectives: To evaluate the count of Th17+ lymphocytes in patients with SAPHO syndrome and psoriatic arthritis before and under treatment with secukinumab. Methods: Periphereal blood was derived from 4 patients with SAPHO syndrome and 4 patients with psoriatic arthritis, respectively before and under 12 week treatment with secukinumab 300mg (dosage: 4 times weekly, then monthly). All patients had received at least one conventional DMARDs and one TNF blocking agent in their medical history. All patients showed active disease with elevated scores of DAS28 and/or HAQ, for SAPHO patients the activity scores of osteitis (from 0 to 6) and PPP (0-6) were estimated by physician. The blood specimen were separated in EDTA containing tubes to separate lymphocytes, which were measured using FACS analysis to evaluate the fraction of Th 17+/CD4+ lymphocytes. The Ethics Committee of Saarland has proven the study, all patients gave their consent to take part in the study. Results: The Th17+lymphocytes were not detectable in 4 patients with psoriatic arthritis and 2 of 4 SAPHO patients before and under 12 week treatment with secukinumab. In 2 of 4 SAPHO patients the fractions of Th17+ lymphocytes were prominent prior to secukinumab application; after treatment duration of 12 weeks one of both developed a depletion of Th17+ cells ( figure) , the other SAPHO patient a Th17+ cell reduction. Only the two SAPHO patients with diminishing Th17+ lymphocytes have developed treatment response evaluated by reduction of HAQ score (from 1.75 to 1.25), osteitis score (4.5 to 3.0), and PPP score (5.0 to 4.0). Three of 4 psoriatic arthritis patients showed reduced diseases activity under treatment with secukinumab (DAS28 score from 4.22 to 3.45, HAQ 2.25 to 1.5).
Conclusions:
The measurement of Th17+lymphocytes in the periphereal blood of SAPHO patients could be suggested for further evaluation as possible predictor of treatment response by secukinumab. Background: Adult onset Still's disease (AOSD) is an inflammatory disorder of unknown etiology, which is accompanied by increased levels of serum proinflammatory cytokine. Mesenchymal stem cells (MSCs) have immunomodulatory capacities and might be a promising therapeutic option in the treatment of refractory autoimmune diseases. Both cell-to-cell contact and the release of soluble factors mediate immune modulatory functions of MSCs. Objectives: We aimed to determine if MSCs could modulate serum cytokine level in patients with active untreated AOSD, either through paracrine secretion or via direct contacts with the MSCs. Methods: Human peripheral blood mononuclear cells (hPBMCs) from 6 patients with active AOSD were co-cultured for 72 hours with human MSCs (hMSCs at a ratio of 10 to 1). We compared the cytokine levels before and after direct or indirect (transwell cultures) exposition to activated mononuclear cells (LPS, 10ng/ml) or T cell-inducing conditions (anti-CD3 [5 μg/ml], anti-CD28 [5 μg/ml], recombinant human IL-2 [5 ng/ml]). Cytokine levels were detected by multiplex cytokine detection kit by flow cytometry, or ELISA with culture supernatant. In vitro platform for studying the effects of MSCs on individual cytokines, the Wilcoxon signed-rank test was employed for comparison of serum cytokine levels. Results: Treatment of mononuclear cells with hMSCs resulted in significant reduction of mean TNF-α level (mean 463.4 pg/ml vs 137.8 pg/ml, p<0.05) and IL-1 β (mean 1887.1 pg/ml vs 1127.9 pg/ml, p<0.05). When the hMSCs were present during the T-cell differentiation, there was a significant decrease in the mean secreted TNF-α (mean 10953.5 pg/ml vs 454.9 pg/ml, p<0.05), IFN-γ (mean 14301.0 pg/ml vs 5090.4 pg/ml, p<0.05) and sIL-2 receptor (mean 3550.8 pg/ml vs 2506.4 pg/ml, p<0.05). On the contrary, level of TGF-β was significantly increased (mean 4088.8 pg/ml vs 5104.8 pg/ml, p<0.05). But, there was a significant increase in the amount of IL-6 (mean 2215.5 pg/ml vs 25130.6 pg/ml, p<0.05) and IL-17 α (mean 1357.0 pg/ml vs 2453.6 pg/ml, p<0.05). Two chamber experiments also showed similar pattern of cytokine modulation.
This preliminary experiment demonstrated that MSCs can modulate cyokine profiles of AOSD mononuclear cells by decreasing pro-inflammatory cytokines, and increasing anti-inflammatory cytokine such as TGF-β. However, up-regulation of IL-6 and IL-17 might be a hurdle to overvome in the clinical application of MSCs in AOSD patients. 
